The clinical application of targeted α- and β-radionuclide therapies for prostate cancer is rapidly evolving with the development of novel next-generation radiopharmaceutical treatments, including 177Lu-PSMA, which target bone and extraskeletal metastases, gaining significant attraction as potential therapeutic options for patients with mCRPC. This evidence concerns the gene FOLH1 and Familial prostate cancer.